A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients

NCT02017717 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

529

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent Glioblastoma

Interventions

BIOLOGICAL: Nivolumab
BIOLOGICAL: Bevacizumab
BIOLOGICAL: Ipilimumab

Sponsor

Bristol-Myers Squibb